EE392 Number Needed to Treat (NNT) Comparing Sacituzumab Govitecan and Single-Agent Chemotherapy in Relapsed or Refractory Metastatic Triple-Negative Breast Cancer
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.688
https://www.valueinhealthjournal.com/article/S1098-3015(24)00803-9/fulltext
Title :
EE392 Number Needed to Treat (NNT) Comparing Sacituzumab Govitecan and Single-Agent Chemotherapy in Relapsed or Refractory Metastatic Triple-Negative Breast Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00803-9&doi=10.1016/j.jval.2024.03.688
First page :
Section Title :
Open access? :
No
Section Order :
10158